Current Cancer Drug Targets

Editor-in-Chief

Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)

Personal Subscription
Become EABM
Become Reviewer
Call for Editor
Volume: 20 Issue: 6, July 2020



Meet Our Editorial Board Member free to download

Volume:20   Issue: 6
Pp: 391-391
M.P. Carty
DOI: 10.2174/156800962006200707220550
Published on: 07 July, 2020



Updated Review and Perspective on 20S Proteasome Inhibitors in the Treatment of Lung Cancer

Volume:20   Issue: 6
Pp: 392-409
Sagar O. Rohondia*, Zainab Sabry Othman Ahmed and Q. Ping Dou*
DOI: 10.2174/1568009620666200226094000
Published on: 25 February, 2020




COVID-19 Pandemic: Experiences in China and Implications for its Prevention and Treatment Worldwide

Volume:20   Issue: 6
Pp: 410-416
Ning-Ning Liu*, Jing-Cong Tan, Jingquan Li, Shenghui Li*, Yong Cai* and Hui Wang*
DOI: 10.2174/1568009620666200414151419
Published on: 14 April, 2020




The Therapeutic Potential of MEK1/2 Inhibitors in the Treatment of Gynecological Cancers: Rational Strategies and Recent Progress

Volume:20   Issue: 6
Pp: 417-428
Sadaf Ghanaatgar-Kasbi, Majid Khazaei, Azam Rastgar-Moghadam, Gordon A. Ferns, Seyed Mahdi Hassanian and Amir Avan*
DOI: 10.2174/1568009620666200424144303
Published on: 24 April, 2020




Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy

Volume:20   Issue: 6
Pp: 429-460
Mohammed Shaaban, Heba Othman, Takwa Ibrahim, Mariam Ali, Mohamed Abdelmoaty, Abdel-Rahman Abdel-Kawi, Ahmed Mostafa, Aya El Nakeeb, Heba Emam and Alaa Refaat*
DOI: 10.2174/1568009620666200422081912
Published on: 21 April, 2020




CircRNA SCARB1 Promotes Renal Cell Carcinoma Progression Via Mir- 510-5p/SDC3 Axis

Volume:20   Issue: 6
Pp: 461-470
Jijian Sun*, Shijie Pan, Hongquan Cui and Hao Li
DOI: 10.2174/1568009620666200409130032
Published on: 09 April, 2020